TY - JOUR
T1 - Antibody development against biologic agents used for the treatment of inflammatory bowel disease and antibody prevention with immunosuppressives
AU - Bots, Steven
AU - Vande Casteele, Niels
AU - Brandse, Johannan F.
AU - Lowenberg, Mark
AU - Feagan, Brian G.
AU - Sandborn, William J.
AU - Levesque, Barrett G.
AU - Khanna, Reena
AU - Jairath, Vipul
AU - Macdonald, John K.
AU - D'Haens, Geert
N1 - Publisher Copyright: © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2016/5/2
Y1 - 2016/5/2
N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objectives are to systematically review the prevalence of immunogenicity to biologics with the use of different test assays, the impact of ADA formation on the efficacy and safety of biologics and the influence of combination therapy on immunogenicity in patients with IBD.
AB - This is the protocol for a review and there is no abstract. The objectives are as follows: The primary objectives are to systematically review the prevalence of immunogenicity to biologics with the use of different test assays, the impact of ADA formation on the efficacy and safety of biologics and the influence of combination therapy on immunogenicity in patients with IBD.
UR - http://www.scopus.com/inward/record.url?scp=84966389788&partnerID=8YFLogxK
U2 - https://doi.org/10.1002/14651858.CD012147
DO - https://doi.org/10.1002/14651858.CD012147
M3 - Review article
SN - 1469-493X
VL - 2016
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 5
M1 - CD012147
ER -